A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...

EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...

Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic ...

Stifel analyst Jonathan Block downgraded Zoetis (ZTS) to Hold from Buy with a price target of $160, down from $165. The firm contends that the ...